In a crucial development for public health, Health Canada has extended its approval for GlaxoSmithKline’s Arexvy vaccine to include adults aged 50 to 59 who face a heightened risk from respiratory syncytial virus (RSV) due to underlying health conditions. This expanded approval marks a significant move in Canada’s battle against RSV, a respiratory virus that, […]
GSK plc (LSE/NYSE: GSK) and Aiolos Bio, Inc. (Aiolos) have announced a significant agreement, where GSK will acquire Aiolos, a clinical-stage biopharmaceutical company focusing on respiratory and inflammatory conditions. The acquisition, valued at $1 billion upfront and potential regulatory milestone payments of up to $400 million, signifies GSK’s commitment to addressing the unmet needs of […]
GSK has secured the approval of the US Food and Drug Administration (FDA) for the company’s Jesduvroq (daprodustat) for anaemia of chronic kidney disease (CKD) in adults on dialysis. Jesduvroq is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor indicated for the daily once treatment of anaemia due to CKD in adults on dialysis for at […]
Wave Life Sciences and GSK have forged a partnership to discover and develop oligonucleotide therapeutics, focusing on new genetic targets, for respiratory diseases. The discovery collaboration with an initial four-year research term is expected to advance Wave Life Sciences’ preclinical RNA editing program, WVE-006, to treat alpha-1 antitrypsin deficiency (AATD), a disease that impacts the […]